Evidence map›Paper›PMID 35432354›Full record

ArticleFrontiers in immunology2022

Frequency of CXCR3

Rafael Tibúrcio, Gopalan Narendran, Beatriz Barreto-Duarte, Artur T L Queiroz, Mariana Araújo-Pereira, Selvaraj Anbalagan, Kaustuv Nayak, Narayanan Ravichandran, Rajasekaran Subramani, Lis R V Antonelli and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 4 countries.

Rafael TibúrcioLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Gopalan NarendranDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Beatriz Barreto-DuarteLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Artur T L QueirozMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Mariana Araújo-PereiraLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Selvaraj AnbalaganDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Kaustuv NayakDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Narayanan RavichandranGovernment Hospital of Thoracic Medicine, Chennai, India.
Rajasekaran SubramaniDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Lis R V AntonelliLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil.
Kumar SatagopanGovernment Hospital of Thoracic Medicine, Chennai, India.
Komathi AnbalaganGovernment Hospital of Thoracic Medicine, Chennai, India.
Brian O PorterHIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Alan SherImmunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Soumya SwaminathanDepartment of Clinical Research, National Institute for Research in Tuberculosis, Chennai, India.
Irini SeretiHIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Bruno B AndradeLaboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
National Institute of Research in Tuberculosis · INFundação Oswaldo Cruz · BRGovernment Hospital of Thoracic Medicine · INNational Institute of Allergy and Infectious Diseases · USUniversidade Federal da Bahia · BRInternational Centre for Genetic Engineering and Biotechnology · INNational Institutes of Health · USVanderbilt University · US

Funding

Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) DiseaseZIAAI001121 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SERETI, IRINI · 2010 to 2025
$27.2M
6 · The paper itself

Abstract

Background: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a clinical aggravation of TB symptoms observed among a fraction of HIV coinfected patients shortly after the start of antiretroviral therapy (ART). Of note, TB-IRIS is characterized by exacerbated inflammation and tissue damage that occurs in response to the elevated production of CD4 Methods: We performed a comprehensive assessment of the composition of CD8 Results: We found that TB-IRIS individuals display higher frequencies of Antigen-experienced CD8 Conclusion: Our data suggest that TB-IRIS individuals display a distinct profile of memory CD8

Indexed as

HIV InfectionsImmune Reconstitution Inflammatory SyndromeTuberculosisCD8-Positive T-LymphocytesHumansInflammationReceptors, CXCR3T-Lymphocyte SubsetsCXCR3 protein, humanReceptors, CXCR3CD8+ T cellsimmunologic memoryM. tuberculosis infectionnaïve lymphocytesTB-IRIS

Identifiers

PMID35432354
PMCPMC9011055
OpenAlexW4220878869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.